1.Building and effect of vendor cloud platform for stomatological materials
Fangli HE ; Jiqing YANG ; Jianxue ZHOU ; Jing CHEN ; Haibing FAN ; Hong XIN ; Xin BU
Chinese Medical Equipment Journal 2017;38(3):61-63,69
Objective To complete an information chain to support stomatological materials purchase and providing manage-ment.MethodsThe main problems of the materials management information chain were analyzed.The system construction,technical architecture and function design were designed based on B/S and C/S structure.Results The vendor cloud platform completed the information chain for purchase and distribution of stomatological materials,and provided technical support to hospital consumables management.Conclusion The system normalizes stomatological materials management,guarantees the safety,timeliness and accuracy of materials supply,and thus is worthy applying practically.
2.Recombinant goat pox virus expressing PPRV H protein.
Weiye CHEN ; Linmao QU ; Sen HU ; Qianqian HU ; Qian ZHANG ; Haibing ZHI ; Kehe HUANG ; Zhigao BU
Chinese Journal of Biotechnology 2009;25(4):496-502
The purpose of the study is to construct recombinant goat pox virus (GPV) expressing Peste des petits ruminants virus (PPRV) H protein, and to evaluate the immunization effect. Recombinant GPV containing PPRV H gene (rGPV-PPRV-H) was selected and purified by gpt and eGFP utilizing plaque purification, and the final selected recombinant GPV was proved to be purified by PCR. Immunofluorescence and Western blotting showed that the recombinant virus could express H protein of PPRV while infecting lamb testis cells. Six goats were immunized with 2 x 10(6) PFU rGPV-PPRV-H through intradermal injection, and were immunized for the second time at 28 days with the same dose recombinant virus after first immunization. Serum was collected after immunization, and was analyzed for the neutralization antibodies. 21 days after first immunization, the neutralization antibodies of GPV were 40, 80, > or = 80, > or = 80, 40, > or = 80 in turn, and neutralization antibodies of PPRV were 80, 80, 80, 80, 40, 40, 10 in turn; 14 days after second immunization, the neutralization antibodies of GPV were all > or = 80, and the neutralization antibodies of PPRV were > 80, 80, > 80, 80, 80 and 40 in turn. This study established a foundation for the industrialization of the PPRV recombinant GPV vaccine.
Animals
;
Capripoxvirus
;
genetics
;
immunology
;
Goat Diseases
;
immunology
;
prevention & control
;
virology
;
Goats
;
Hemagglutinins, Viral
;
genetics
;
immunology
;
metabolism
;
Peste-des-Petits-Ruminants
;
immunology
;
prevention & control
;
Peste-des-petits-ruminants virus
;
genetics
;
immunology
;
Recombinant Proteins
;
genetics
;
immunology
;
metabolism
;
Vaccines, Combined
;
immunology
;
Vaccines, Synthetic
;
immunology
;
Viral Vaccines
;
immunology